1Lanaspa MA, Tapia E, Soto V, et al. Uric Acid and fructose: potential biological mechanisms[J]. Semin Nephrol, 2011,31(5): 426-432.
2Calhoun DA, White WB, Krum H, et al. Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial[J]. Circulation, 2011 (5): 40-41.
3Forni V, Wuerzncr G, Pruijm M, et al. Long-term use and tolerability of irbesartan for control of hypertension [J]. Integr Blood Press Control, 2011 (4): 17-26.
4Carey RM. Overview of endocrine systems in primary hypertension [J]. Endocrinol Metab Clin Noah Am, 2011, 40(2): 265-277.
8Willens H J, Davis W, Herrington D M, et al. Relationship of peripheral arterial compliance and standard cardiovascular risk factors[J]. Vase Endovascular Surg, 2003, 37 (3):197.
9Herrington D M, Brown W V, Mosca L, et al. Relationship between arterial stiffness and subclinical aortic atheroselerosis[J]. Circulation, 2004, 110(4): 432.
10Weber T, Auer J, O'Rourke M F, et al. Arterial stiffness,wave reflections, and the risk of coronary artery disease[J].Circulation, 2004,109(2): 184.
